Most established cancer treatments - from chemotherapy and radiation to the 200 drugs out there - have one thing in common.
They're all more or less "one size fits all" treatments, procedures, or regimens.
But the most exciting, promising discoveries - and biggest profits - are made on the frontier. And on the frontier of cancer research is a treatment under development that's going to disrupt the field for the next several decades.
I'm talking about powerful "bespoke" cancer treatments for every patient, using their own bodies to boot.
Not only will this improve and save lives, but it'll also crack open a market worth $25 billion by 2025. It really is a revolutionary development.
But the "Buy" call I'm making today is still trading at "pre-revolutionary" prices...
The Cancer Fight's "A-Bomb"
I can't overstate this. The treatment I'm going to tell you about, as well as the most important company pioneering it, will change cancer treatment the way the atomic bomb changed the face of warfare moving forward.
This biotech "A-bomb" is called immunotherapy, or "IO" to insiders. And it's progressing rapidly.
The technique is straight out of science fiction.
Immunotherapy uses a patient's own immune system - "tweaking" it by either suppressing, stimulating, or enhancing an immune response - to effect a desired change. It can be used to vaccinate people and fight microbial diseases, reduce allergic reactions, suppress the sometimes devastating response to organ transplants, and, most promisingly, help patients destroy their own tumors and beat cancer.
Right now there are more than 1,000 drug trials underway for IO candidates. The trials mainly involve patients whose cancer isn't responding to traditional therapies like chemo or radiation and who are now terminal.
There's good reason to move with haste. The longer we live, the more likely we are to develop some form of cancer. It's always been a killer, but it's becoming a huge problem.
In addition to the human cost, traditional cancer treatments run about $10,000 a month, according to U.S. News & World Report. Insurers, doctors, researchers, regulators, and patients are all on the same page here. That's been an important driver in IO's development.
I'm bullish on this entire segment, and I'm not alone. Barclays expects IO to be worth $25 billion by 2025 - just eight years.
Now let me show you the company I think will reap the most benefit from this "frontier" research.
The Biotech at the Top of the IO Pyramid
Incyte Corp. (Nasdaq: INCY) is one of the leading IO and next-generation oncology drugmakers in the marketplace today.
Its first major drug to market was Jakafi, a drug used to fight a bone-marrow cancer called myelofibrosis, where bone marrow is replaced with scar tissue. That makes the spleen swell as it takes over the job of making red blood cells. Jakafi uses inhibitors to slow or stop the conversion of the bone marrow.
Approved in 2011, Jakafi is well on it…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
Wondering if I should consider selling EKSO Bionics stock and buying one of these in a healthcare field too.